Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. - Wikidata - wikimedia - TriplyDB

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

http://www.wikidata.org/entity/Q37615119

about

Sustainable Risk Management.

P2860

Q42245996-2351B222-DB04-4636-B66C-1B5B7AE75664

P2860

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

http://www.wikidata.org/entity/Q37615119

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@en

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@nl

type

label

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@en

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@nl

prefLabel

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@en

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@nl

P1433

Q37615119-ADA11B90-B888-4772-9646-3DAC7D974940

P1476

Q37615119-66D245FE-CBCF-4575-AC2C-CA4EE205E12A

P2093

Q37615119-41A6803A-588D-4D1E-9779-B53E52E98448

Q37615119-6EFAE782-C0D7-40AA-B8CC-14B15388E4A9

Q37615119-C6BCAEB6-2D91-4964-8923-F7DA124C816C

Q37615119-D555B363-EABE-4909-A355-978ED20B3483

P2860

Q37615119-03919E61-13C9-459D-92C9-92D0F6864B0C

Q37615119-0C61C781-25D9-4C2D-824C-B1244BB96757

Q37615119-0DAF03EC-00C9-482F-B76D-301F1120D120

Q37615119-13BF7C00-1E76-4A7F-9886-7926877193C9

Q37615119-13D1D973-9562-4581-B749-7567DBF79B69

Q37615119-189E0D20-0FDF-4D6D-BBC8-B535DE6E9E6E

Q37615119-192B521B-ABCB-4FD2-9FA5-427C62C20158

Q37615119-1AED6007-8765-494E-B3BF-259723D44883

Q37615119-1B67A263-40E7-4B17-A8AE-9069FA38E1BA

Q37615119-1C856F82-B863-405C-932E-E9BC2D8A8E62

P304

Q37615119-74FD670B-02C0-4569-A2EA-E2E7452B0D35

P31

Q37615119-BD6D8085-2A36-435E-9C47-69CC1EE3D429

P356

Q37615119-8AC9BC5E-B820-41FC-950A-01D1F544B604

P433

Q37615119-ABB936DE-0AFD-4D01-B671-7C60A1E810AB

P478

Q37615119-CAA0784C-679D-4A1A-913A-071175DD6C28

P50

Q37615119-0321BB37-260C-4D74-A0CB-036D2EC72C2E

Q37615119-4BE4D5C3-4EAB-444C-9D0F-557D964A7203

P577

Q37615119-62874E2E-6727-402F-80BA-978239ED97F9

P698

Q37615119-89B3C35F-574E-41CB-BAB1-81DE46B0EC20

P921

Q37615119-850746F7-57CA-4A41-93CA-21874749A852

P932

Q37615119-61E8FF15-9F1F-470A-B559-4A0065AD6214

P356

ARZTEBL.2016.0879

P1433

Deutsches Ärzteblatt international

P1476

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

@en

P2093

Clemens Warnke

http://www.w3.org/2001/XMLSchema#string

Joachim Havla

http://www.w3.org/2001/XMLSchema#string

Reinhard Hohlfeld

http://www.w3.org/2001/XMLSchema#string

Tobias Derfuss

http://www.w3.org/2001/XMLSchema#string

P2860

Disease modifying therapies for relapsing multiple sclerosis

Management of women with multiple sclerosis through pregnancy and after childbirth

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy.

P304

879-886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3238/ARZTEBL.2016.0879

http://www.w3.org/2001/XMLSchema#string

P433

51-52

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28130920

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

5282476

http://www.w3.org/2001/XMLSchema#string